Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled acetylcysteine for invasively ventilated ICU patients with high secretion burden
ACTRN12621001766808Phase 3Not yet recruiting
- Sponsor
- Waikato Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of acetylcysteine in ventilator-associated pneumonia (VAP) and None (2 arms), sponsored by Waikato Hospital. Primary endpoint: PaO2/FiO2 ratio at 48 hours. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on ACTRN12621001766808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001766808.